Immutep Partners with Merck to Conduct P-III Study of Eftilagimod Alfa (Efti) with Keytruda for Treating NSCLC
Shots:
- Immutep & Merck have signed a clinical trial collaboration & supply agreement for P-III (TACTI-004) study of eftilagimod alfa (efti) plus Keytruda & CT to treat NSCLC
- The P-III (TACTI-004) trial will assess efti + Keytruda & CT vs PBO + Keytruda & CT as a 1L treatment of metastatic NSCLC (incl. both squamous & non-squamous subtypes) patients (n=750), irrespective of PD-L1 expression
- As per the agreement, Immutep will be responsible for the P-III trial with Merck providing Keytruda for the same. Both companies will keep commercial rights of their compounds & can carry out other clinical evaluations independently or together in any therapeutic area; can look for marketing authorization in a relevant indication
Ref: Immutep | Image: Immutep
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
